Matrix

Shanghai Yudao Biotechnology Co., Ltd. is a biopharmaceutical company established in 2013, headquartered in Shanghai, China. The company specializes in the development of platforms for drug development, alongside offering medical bioinformatics training. Through its innovative approaches, Yudao Bio aims to enhance biopharmaceutical products and contribute to advancements in the healthcare sector.

Yuan Yu Bio is a biotech firm that focused on the development of innovative microalgae biosynthesis technology.

ExCell Biotech Co., Ltd. was founded in 2013 and is based in China.

Scivita Medical is a technology-focused enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging and high-performance materials for minimally invasive medical procedures. The company offers a range of products, including flexible and rigid endoscopes, designed to enhance the capabilities of medical professionals. Its product lineup features advanced technologies such as ultra-high-definition visualization, 3D imaging, and fluorescence visualization, which facilitate precise diagnostics and treatments. Key offerings include a 4K medical endoscope camera system, integrated 4K-3D endoscope systems, and various single-use endoscopic devices for applications in gynecology, urology, and pulmonology. Scivita Medical aims to provide doctors with innovative tools that improve patient outcomes through enhanced visualization and minimally invasive techniques.

Bota Biosciences designs and develops synthetic bioengineering technology platform for bio-manufacturing. The company develops cloud databases and intelligent control software suitable for biotechnology development and production. Bota Biosciences was founded in 2019 and is based in Hangzhou, China.

Scivita Medical is a technology-focused enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging and high-performance materials for minimally invasive medical procedures. The company offers a range of products, including flexible and rigid endoscopes, designed to enhance the capabilities of medical professionals. Its product lineup features advanced technologies such as ultra-high-definition visualization, 3D imaging, and fluorescence visualization, which facilitate precise diagnostics and treatments. Key offerings include a 4K medical endoscope camera system, integrated 4K-3D endoscope systems, and various single-use endoscopic devices for applications in gynecology, urology, and pulmonology. Scivita Medical aims to provide doctors with innovative tools that improve patient outcomes through enhanced visualization and minimally invasive techniques.

Senti Biosciences is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative gene and cell therapies using its proprietary synthetic biology platform. Founded in 2016, the company aims to address complex diseases through advanced therapeutic solutions. Senti's technology includes engineered allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, which are designed to target and eliminate cancer cells while minimizing damage to healthy tissue. Among its product candidates are SENTI-202, a Logic Gated CAR-NK cell therapy intended for cancer treatment, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences operates as a resident company at Johnson & Johnson Innovation's JLABS in South San Francisco, collaborating with experts in synthetic biology and computation to advance its therapeutic developments.

D3 Bio Inc. is a biotechnology company founded in 2020 and based in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company adopts a unique approach to medicine development by first identifying significant unmet patient and market needs, particularly in areas where current treatments are inadequate. This understanding informs their research and guides the selection of appropriate scientific and technological methods to define their drug development strategy. Through this differentiated approach, D3 Bio aims to address critical health challenges and improve clinical outcomes for patients.

Bota Biosciences designs and develops synthetic bioengineering technology platform for bio-manufacturing. The company develops cloud databases and intelligent control software suitable for biotechnology development and production. Bota Biosciences was founded in 2019 and is based in Hangzhou, China.

Bota Biosciences designs and develops synthetic bioengineering technology platform for bio-manufacturing. The company develops cloud databases and intelligent control software suitable for biotechnology development and production. Bota Biosciences was founded in 2019 and is based in Hangzhou, China.

Bota Biosciences designs and develops synthetic bioengineering technology platform for bio-manufacturing. The company develops cloud databases and intelligent control software suitable for biotechnology development and production. Bota Biosciences was founded in 2019 and is based in Hangzhou, China.

Lumist is an integrated study app where learning starts with asking questions. With the snap of a picture, students can receive detailed step-by-step solutions for any academic question they have. The app also features a variety of livestream and pre-recorded teaching sessions to explain key concepts and prepare students for exams. Lumist is available for download on iOS and Android.

Lansion Biotechnology is specialized in research & development, production, sell, services of in vitro diagnostic reagents and devices. With its advanced technology concept, Lansionbio provides equioment, reagents and services to world-wild clients according to their needs.

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus. The company was founded in 2003 and is headquartered in San Diego, California.

Chameleon Biosciences Inc. specializes in developing gene therapy solutions using Adeno Associated Virus (AAV) technology to address rare genetic diseases. Founded in 2017 and based in San Anselmo, California, the company focuses on delivering therapeutic proteins to targeted tissues while minimizing immune responses to enhance gene delivery and reduce immunogenicity. Chameleon aims to transform the treatment landscape for genetic disorders, particularly in infants, where a significant percentage of fatalities are attributed to these conditions. The company is dedicated to ensuring that affected children receive accurate, lower-dose treatments that can be administered multiple times as needed. By masking foreign proteins and shielding the viral capsid from antibodies, Chameleon seeks to increase the range of diseases that can be treated effectively, thereby improving patient outcomes and quality of life.

SA Biotech is a Healthcare company.

Si'ao Biotechnology engages in the development and production of genetic engineering vaccines and test kits.

Adlai Nortye Biopharma Co., Ltd. is a biopharmaceutical company based in Hangzhou, China, focused on the research and development of innovative treatments for cancer and metabolic diseases. Founded in 2004 and formerly known as Sinopep Pharmaceutical Inc., the company has shifted its emphasis to oncology and immuno-oncology. Adlai Nortye is committed to improving patient outcomes through the discovery and commercialization of differentiated medicines. With a solid foundation in peptide and protein drug development, the company has broadened its scope to include small molecules and therapeutic antibodies. It holds 23 granted patents and has published 7 PCT applications. Through strategic collaborations with global partners, Adlai Nortye has established a diverse pipeline of programs ranging from early pre-clinical stages to those ready for phase 3 clinical trials.

Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus. The company was founded in 2003 and is headquartered in San Diego, California.

Chengdu 23Mofang Biotechnology Co., Ltd. specializes in genetic testing services, primarily focusing on saliva-based testing. Founded in 2015 and based in Chengdu, China, the company provides insights into ancestral origins, genetic risks, and traits by analyzing samples and delivering detailed reports through a mobile application. 23Mofang aims to leverage the Internet and genetic testing to create a comprehensive life data database, with a mission to enhance individual well-being through accessible genetic information. The company positions itself as a reliable technology enterprise that benefits society by enabling users and their families to proactively address potential health issues.